

118TH CONGRESS
2D SESSION

H. R. 9598

AN ACT

To amend the Office of National Drug Control Policy Reauthorization Act to reauthorize such Office, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Office of National
3 Drug Control Policy Reauthorization Act of 2024”.

4 **SEC. 2. OFFICE OF NATIONAL DRUG CONTROL POLICY RE-**
5 **AUTHORIZATION.**

6 (a) AMENDMENTS TO THE OFFICE OF NATIONAL
7 DRUG CONTROL POLICY REAUTHORIZATION ACT OF
8 1998.—The Office of National Drug Control Policy Reau-
9 thorization Act of 1998 (21 U.S.C. 1701 et seq.) is
10 amended—

11 (1) in section 702 (21 U.S.C. 1701)—

12 (A) in paragraph (2)(A)(ii), by striking
13 “Government Reform” and inserting “Account-
14 ability”;

15 (B) in paragraph (3)—

16 (i) in subparagraph (L), by striking “;
17 and” and inserting a semicolon;

18 (ii) in subparagraph (M), by striking
19 the period at the end and inserting “;
20 and”; and

21 (iii) by adding at the end the fol-
22 lowing:

23 “(N) tertiary prevention support or serv-
24 ices, including opioid antagonists or overdose
25 reversal agents such as naloxone, and other

1 harm reduction activities such as overdose and
2 drug detection testing.”;

3 (C) by amending paragraph (7) to read as
4 follows;;

5 “(7) EMERGING DRUG THREAT.—The term
6 ‘emerging drug threat’ means the occurrence of a
7 new and growing trend in the illicit use or misuse
8 of a drug, class of drugs, or non-controlled sub-
9 stance, or a new or evolving method of drug con-
10 sumption or trafficking, including rapid expansion in
11 the supply of or demand for such a drug or sub-
12 stance.”.

13 (D) in paragraph (9), by striking “drug
14 laws” and inserting the following: “drug, trade,
15 and illicit drug trafficking laws”;

16 (E) in paragraph (10), by inserting after
17 “demand reduction,” the following: “illicit drug
18 trafficking,”;

19 (F) by redesignating paragraphs (15),
20 (16), and (17) as paragraphs (17), (18), and
21 (19), respectively;

22 (G) by inserting after paragraph (14) the
23 following new paragraph:

24 “(15) PRECURSOR CHEMICAL.—

1 “(A) IN GENERAL.—The term ‘precursor
2 chemical’ includes a listed chemical and an un-
3 regulated precursor.

4 “(B) LISTED CHEMICAL.—The term ‘listed
5 chemical’ has the meaning given that term in
6 section 102 of the Controlled Substances Act
7 (21 U.S.C. 802).

8 “(C) UNREGULATED PRECURSOR.—The
9 term ‘unregulated precursor’—

10 “(i) means any chemical used in the
11 production of illicit drugs that has not
12 been identified as a listed chemical under
13 the Controlled Substances Act; and

14 “(ii) does not include a solvent or rea-
15 gent.

16 “(16) STATE.—The term ‘State’ means each of
17 the several States of the United States, the District
18 of Columbia, and each territory or possession of the
19 United States.”;

20 (H) in paragraph (19), as so redesign-
21 nated—

22 (i) by redesignating subparagraphs
23 (G) and (H) as subparagraphs (H) and
24 (I), respectively; and

1 (ii) by inserting after subparagraph
2 (F) the following:

3 “(G) activities to map, track, dismantle,
4 and disrupt the financial enablers of drug traf-
5 ficking organizations, transnational criminal or-
6 ganizations, and money launderers involved in
7 the manufacture and trafficking of drugs in the
8 United States and in foreign countries;” and

9 (I) by inserting at the end the following:

10 “(20) UNITED STATES.—The term ‘United
11 States’, when used in a geographical sense, means
12 all of the States, the District of Columbia, and the
13 territories and possessions of the United States, and
14 any waters within the jurisdiction of the United
15 States.

16 “(21) EVIDENCE.—The term ‘evidence’ has the
17 meaning given that term in section 3561 of title 44,
18 United States Code.”;

19 (2) in section 703(d) (21 U.S.C. 1702(d))—

20 (A) in paragraph (5)(B), by striking “ac-
21 cepted by a contractor to be used in its per-
22 formance of a contract for the Office.” and in-
23 serting the following: “accepted—

1 “(i) by a contractor (or subcontractor
2 thereof at any tier) for use in its perform-
3 ance of a contract for the Office; or

4 “(ii) by a grant recipient (or sub-
5 grantee thereof at any tier) for use in car-
6 rying out an award related to a fund ad-
7 ministered by the Office.”; and

8 (B) in paragraph (6), by inserting after
9 “paragraph (5)” the following: “and the reg-
10 istry shall be sent to the appropriate Congres-
11 sional committees”;

12 (3) in section 704 (21 U.S.C. 1703)—

13 (A) in subsection (a)(1)(C), by striking
14 “shall” and inserting “may”;

15 (B) in subsection (b)—

16 (i) in paragraph (16), by inserting
17 after “to treat addiction” the following: “,
18 encourage primary substance use preven-
19 tion, and increase accessibility and effec-
20 tiveness of life-saving opioid antagonists or
21 reversal agents, such as naloxone”;

22 (ii) by striking paragraph (20);

23 (iii) by redesignating paragraph (21)
24 as paragraph (20);

1 (iv) in paragraph (20), as so redesignated,
2 nated, by striking the period at the end
3 and inserting “; and”; and

4 (v) by inserting at the end the following:
5

6 “(21) shall coordinate with the Secretary of
7 Homeland Security, the Attorney General, and the
8 Secretary of State regarding the status of the enforcement
9 of clauses (i) and (ii) of subparagraph (A)
10 and subparagraph (B) of section 237(a)(2) (8
11 U.S.C. 1227(a)(2)) and subparagraphs (A) and (C)
12 of section 212(a)(2) (8 U.S.C. 1182(a)(2)) for the
13 purposes of ensuring such drug control and illicit
14 drug trafficking enforcement activities are adequately
15 resourced.”;

16 (C) in subsection (c)—

17 (i) in paragraph (1)(C), by striking
18 “supply reduction, and State, local, and
19 tribal affairs, including any drug law enforcement
20 activities” and inserting the following: “supply reduction,
21 accessibility to life-saving opioid antagonists or reversal
22 agents, such as naloxone, and State, local,
23 and Tribal affairs, including any drug related
24 law enforcement activities”;
25

1 (ii) in paragraph (3)(C)—

2 (I) in clause (ii), by inserting
3 after “United States” the following: “,
4 including at and between the ports of
5 entry,”;

6 (II) in clause (iii), by striking “;
7 and” and inserting a semicolon;

8 (III) in clause (iv), by striking
9 the period at the end and inserting “;
10 and”; and

11 (IV) by inserting at the end the
12 following new clause:

13 “(v) requests funding for activities
14 that facilitate illicit drug use, but not in-
15 cluding overdose reversal medications, drug
16 checking, or testing technology.”;

17 (D) in subsection (d)(8)(F)(ii), by striking
18 “and at United States ports of entry by officers
19 and employees of National Drug Control Pro-
20 gram agencies and domestic and foreign law en-
21 forcement officers” and inserting the following:
22 “and at and between United States ports of
23 entry by officers and employees of National
24 Drug Control Program agencies and domestic
25 and foreign law enforcement officers”;

1 (E) in subsection (i)—

2 (i) in paragraph (1)(A), by striking
3 “to address illicit drug use issues” and in-
4 serting the following: “to address illicit
5 drug use, prevention and treatment of
6 overdose and addiction, and law enforce-
7 ment activities”; and

8 (ii) in paragraph (2), by striking
9 “2023” and inserting “2031”; and

10 (F) in subsection (k)—

11 (i) in the heading, by striking “HARM
12 REDUCTION PROGRAMS” and inserting
13 “SUBSTANCE USE PREVENTION, HARM
14 REDUCTION, AND LIFE-SAVING TREAT-
15 MENT PROGRAMS”; and

16 (ii) in the first sentence, by inserting
17 after “drug addiction and use” the fol-
18 lowing: “with the primary goal being the
19 prevention of initial or continued use and
20 the fostering of life-saving opioid antago-
21 nists or reversal agents, such as naloxone”;

22 (4) in section 705 (21 U.S.C. 1704)—

23 (A) in subsection (a)(3)—

24 (i) in subparagraph (A), by inserting
25 after “Federal Government” the following:

1 “and such lands owned by a foreign prin-
2 cipal (as such term in defined in section
3 1(b) of the Foreign Agents Registration
4 Act of 1938 (22 U.S.C. 611))”;

5 (ii) in subparagraph (B)—

6 (I) by inserting after “the pre-
7 ceding year” the following: “, along
8 with historical comparisons over the
9 prior 20 years,”;

10 (II) in clause (i)—

11 (aa) by inserting after “seiz-
12 ing drugs,” the following: “in-
13 cluding precursor chemicals,”;
14 and

15 (bb) by striking “; and” and
16 inserting a semicolon;

17 (III) in clause (ii), by striking
18 the period at the end and inserting “;
19 and”;

20 (IV) by inserting at the end the
21 following new clause:

22 “(iii) the effects of trends of encoun-
23 ters of inadmissible aliens at and between
24 the ports of entry, and the effect of any in-
25 creases or changes in the level of trade and

1 travel, on the capacity and ability of the
2 Department of Homeland Security compo-
3 nents to interdict and prevent the unlawful
4 entry of illicit drugs into the United States
5 by any means.”; and

6 (iii) in subparagraph (D)—

7 (I) by inserting after “the pre-
8 ceding year” the following: “, along
9 with historical comparisons over the
10 prior 20 years,”; and

11 (II) in clause (iii), by inserting
12 after “seizing drugs,” the following:
13 “including precursor chemicals,”;

14 (B) in subsection (e)(2), by inserting be-
15 fore the period at the end the following: “and
16 \$3,000,000 for each of fiscal years 2025
17 through 2031”; and

18 (C) in subsection (f)—

19 (i) in paragraph (2), by inserting after
20 “agency shall” the following: “, in accord-
21 ance with guidelines issued by the Director
22 for standard definitions, identification, and
23 review procedures,”; and

24 (ii) by striking paragraph (4);

25 (5) in section 706 (21 U.S.C. 1705)—

- 1 (A) in subsection (c)—
- 2 (i) in paragraph (1)—
- 3 (I) by striking subparagraph (D);
- 4 (II) in subparagraph (H)—
- 5 (aa) by inserting after
- 6 “identifying existing” the fol-
- 7 lowing: “evidence,”; and
- 8 (bb) by striking “will obtain
- 9 such data” and inserting “will
- 10 ensure such data is obtained”;
- 11 (III) in subparagraph (J)(ii), by
- 12 inserting “evidence,” before “data”;
- 13 (IV) in subparagraph (L), by in-
- 14 serting “evidence” after “Such other”;
- 15 and
- 16 (V) in subparagraph (M)(iv), by
- 17 inserting “storing and retrieving,”
- 18 after “collecting,”;
- 19 (ii) in paragraph (2)—
- 20 (I) by redesignating subpara-
- 21 graphs (E) and (F) as subparagraphs
- 22 (G) and (H), respectively; and
- 23 (II) by inserting after subpara-
- 24 graph (D) the following new subpara-
- 25 graphs:

1 “(E) The Administrator of the Office of
2 Information and Regulatory Affairs.

3 “(F) The Chief Data Officers Council.”;

4 (iii) in paragraph (3)—

5 (I) in subparagraph (B)(ii)—

6 (aa) in subclause (I), by
7 striking “; and” and inserting a
8 semicolon;

9 (bb) in subclause (II), by
10 striking the period at the end
11 and inserting “; and”; and

12 (cc) by inserting at the end
13 the following new subclause:

14 “(III) an analysis of the effects
15 of trends of encounters of inadmis-
16 sible aliens at and between the ports
17 of entry, and the effect of any in-
18 creases or changes in the level of
19 trade and travel, on the capacity and
20 ability of the Department of Home-
21 land Security to interdict and prevent
22 the unlawful entry of illicit drugs into
23 the United States by any means.”;
24 and

1 (II) by adding at the end the fol-
2 lowing new subparagraph:

3 “(D) REQUIREMENT FOR CARIBBEAN BOR-
4 DER COUNTERNARCOTICS STRATEGY.—

5 “(i) PURPOSES.—The Caribbean Bor-
6 der Counternarcotics Strategy shall—

7 “(I) set forth the strategy of the
8 Federal Government for preventing
9 the illegal trafficking of drugs through
10 the Caribbean region into the United
11 States, including through ports of
12 entry, between ports of entry, and
13 across air and maritime approaches;

14 “(II) state the specific roles and
15 responsibilities of each relevant Na-
16 tional Drug Control Program agency
17 for implementing the strategy;

18 “(III) identify the specific re-
19 sources required to enable the relevant
20 National Drug Control Program agen-
21 cies to implement the strategy, to the
22 extent practicable; and

23 “(IV) be designed to promote,
24 and not hinder, legitimate trade and
25 travel.

1 “(ii) SPECIFIC CONTENT RELATED TO
2 PUERTO RICO AND THE UNITED STATES
3 VIRGIN ISLANDS.—The Caribbean Border
4 Counternarcotics Strategy shall include—

5 “(I) a strategy to prevent the il-
6 legal trafficking of drugs to or
7 through Puerto Rico and the United
8 States Virgin Islands, including meas-
9 ures to substantially reduce drug-re-
10 lated violent crime on such islands;
11 and

12 “(II) recommendations for addi-
13 tional assistance or authorities, if any,
14 needed by Federal, State, and local
15 law enforcement agencies relating to
16 the strategy, including an evaluation
17 of Federal technical and financial as-
18 sistance, infrastructure capacity build-
19 ing, and interoperability deficiencies.”;
20 and

21 (iv) in paragraph (5), by striking
22 “data” each place it appears and inserting
23 “evidence, data,”;
24 (B) in subsection (f)—

1 (i) in paragraph (1), by striking “pub-
2 licly available in a machine-readable for-
3 mat” and inserting the following: “publicly
4 available as an open Government data
5 asset (as such term is defined in section
6 3502 of title 44, United States Code)”;

7 (ii) in paragraph (2), by inserting
8 after “searchable format” the following:
9 “available for bulk download to the extent
10 practicable”; and

11 (iii) by amending paragraph (3) to
12 read as follows:

13 “(3) DATA.—The data included in the Drug
14 Control Data Dashboard shall be updated annually
15 with final data, and to the extent practicable, up-
16 dated quarterly with provisional data, that aligns
17 with the goals of the performance measurement sys-
18 tem required under subsection (h) and include, at a
19 minimum, the following:

20 “(A) For each substance identified by the
21 Director as having a significant impact on illicit
22 drug use in the United States, data sufficient
23 to—

1 “(i) assess supply reduction efforts,
2 including, to the extent practicable, the
3 total amount of substances seized;

4 “(ii) assess drug use behaviors;

5 “(iii) estimate the prevalence of sub-
6 stance use disorders;

7 “(iv) show the number of fatal and
8 non-fatal overdoses; and

9 “(v) assess the provision of substance
10 use disorder treatment.

11 “(B) Any quantifiable measures the Direc-
12 tor determines to be appropriate to detail
13 progress toward the achievement of the goals of
14 the National Drug Control Strategy, including,
15 to the extent practicable, data disaggregated by
16 specific geographic areas or sub-populations of
17 interest.

18 “(C) Data sufficient to assess the effective-
19 ness of such substance use disorder treatments.

20 “(D) To the extent practicable, data suffi-
21 cient to show the extent of prescription drug di-
22 version, trafficking, and misuse in the calendar
23 year and each of the previous 3 calendar years.

24 “(E) Any quantifiable measures the Direc-
25 tor determines to be appropriate to detail

1 progress toward the achievement of the goals of
2 the National Drug Control Strategy, including
3 to the extent practicable, data disaggregated by
4 specific geographic areas or sub-populations of
5 interest.”; and

6 (C) in subsection (g)(2)—

7 (i) in subparagraph (D), by striking
8 “narcotics” and inserting “drugs”;

9 (ii) in subparagraph (E), by striking
10 “drug use” and inserting “illicit drug use
11 and misuse”; and

12 (iii) in subparagraph (F), by striking
13 “drug use” and inserting “illicit drug use
14 and misuse”;

15 (6) in section 707 (21 U.S.C. 1706)—

16 (A) in subsection (l)(2)(F), by inserting
17 “and authorities enforcing illicit drug traf-
18 ficking laws” after “task forces”;

19 (B) in subsection (m)(2), by inserting “,
20 authorities enforcing illicit drug trafficking
21 laws,” after “agencies”;

22 (C) in subsection (p)—

23 (i) in paragraph (5), by striking “;
24 and” and inserting a semicolon;

1 (ii) in paragraph (6), by striking the
2 period at the end and inserting “; and”;
3 and

4 (iii) by inserting at the end the fol-
5 lowing new paragraph:

6 “(7) \$298,579,000 for each of fiscal years 2025
7 through 2031.”;

8 (D) in subsection (r)(3), by striking “ad-
9 diction”;

10 (E) in subsection (s)—

11 (i) in the matter before paragraph
12 (1), by striking “The Director” and insert-
13 ing “Except as provided in subsection
14 (t)(2), the Director”;

15 (ii) in paragraph (2), by striking “;
16 and” and inserting a semicolon;

17 (iii) in paragraph (3), by striking the
18 period at the end and inserting “; and”;
19 and

20 (iv) by adding at the end the fol-
21 lowing:

22 “(4) enhancing fentanyl seizure and interdiction
23 activities.”; and

24 (F) by adding at the end the following:

1 “(t) SUPPLEMENTAL GRANTS FOR FENTANYL
2 INTERDICTION ACTIVITIES.—

3 “(1) MINIMUM ALLOCATION OF FUNDS FOR
4 FENTANYL INTERDICTION ACTIVITIES.—Of the
5 amounts allocated for grants under subsection (s),
6 not less than \$5,000,000 shall be allocated for the
7 purpose of making grants under subsection (s)(4).

8 “(2) ADDITIONAL FUNDS.—In addition to
9 amounts allocated under subparagraph (A) for the
10 purpose of making grants under subsection (s)(4),
11 the Director may use amounts otherwise appro-
12 priated to carry out this section for such purpose.

13 “(u) ADDITIONAL JUDICIARY PROSECUTORIAL RE-
14 SOURCES.—

15 “(1) TEMPORARY REASSIGNMENT OF ASSIST-
16 ANT UNITED STATES ATTORNEYS.—

17 “(A) AUTHORITY.—The Attorney General
18 may identify assistant United States attorneys
19 who may be made available for temporary reas-
20 signment under subsection (b)(2) for a period
21 of time determined by the Attorney General in
22 coordination with the Director, during which an
23 assistant United States attorney shall prioritize
24 the investigation and prosecution of organiza-

1 tions and individuals trafficking in fentanyl or
2 fentanyl analogues.

3 “(B) EXTENSION OF REASSIGNMENT.—
4 Such reassignment may be extended by the At-
5 torney General for such time as may be nec-
6 essary to conclude any ongoing investigation or
7 prosecution in which the assistant United
8 States attorney is engaged.

9 “(2) PROCESS FOR TEMPORARY REASSIGN-
10 MENT.—The Attorney General may establish a proc-
11 ess under which the Director, in consultation with
12 the Executive Boards of each designated high inten-
13 sity drug trafficking area, may request such an as-
14 sistant United States attorney to be so temporarily
15 reassigned.

16 “(v) USE OF FUNDS TO COMBAT FENTANYL TRAF-
17 FICKING.—

18 “(1) REQUIREMENT.—As part of the docu-
19 mentation that supports the President’s annual
20 budget request for the Office, the Director shall sub-
21 mit to Congress a report describing the use of
22 HIDTA funds for the purposes of enhancing
23 fentanyl seizure and interdiction activities under
24 subsection (s)(4) or (t) and to investigate and pros-
25 ecute organizations and individuals trafficking in

1 fentanyl or fentanyl analogues in the prior calendar
2 year.

3 “(2) CONTENTS.—The report shall include—

4 “(A) the amounts of fentanyl or fentanyl
5 analogues seized by HIDTA-funded initiative in
6 the area during the previous year; and

7 “(B) law enforcement intelligence and pre-
8 dictive data from the Drug Enforcement Ad-
9 ministration showing patterns and trends in
10 abuse, trafficking, and transportation in
11 fentanyl and fentanyl analogues.

12 “(w) PROTECTION FROM UNREASONABLE SEARCH
13 AND SEIZURE.—Any program or activity that receives
14 funds made available under this section shall be conducted
15 in a manner consistent with the requirements of the
16 Fourth Amendment to the Constitution of the United
17 States.

18 “(x) REPORT ON DATA ANALYTICAL SERVICES PRO-
19 GRAM.—

20 “(1) REPORT.—With respect to the Data Ana-
21 lytical Services program (formally known as Hemi-
22 sphere), and any successor program, the Director
23 shall submit to the Committee on Oversight and Ac-
24 countability and the Committee on the Judiciary of
25 the House of Representatives, and the Committee on

1 the Judiciary of the Senate a report every two years
2 on any activities of the program—

3 “(A) funded by the Office; and

4 “(B) carried out in two years prior to the
5 submission of the report.

6 “(2) CONTENTS OF REPORT.—The report re-
7 quired by paragraph (1) shall include the following:

8 “(A) A documentation of any activities of
9 the Data Analytical Services program, includ-
10 ing—

11 “(i) the amount of searches conducted
12 for each HIDTA; and

13 “(ii) each requesting local law enforce-
14 ment jurisdiction.

15 “(B) Information on how the program was
16 funded and how funds were expended under the
17 program, including information on any—

18 “(i) funding sources derived from
19 each HIDTA’s funding allocation for a
20 HIDTA, or any other source of funding,
21 for the program; and

22 “(ii) payments made by the program
23 to any non-governmental entity or external
24 vendor.

1 “(C) A description of any policies and
2 guidelines provided to HIDTA personnel and
3 local law enforcement jurisdictions governing
4 the operation of the program in order to ensure
5 that such program does not infringe on rights
6 protected under the Fourth Amendment or vio-
7 late legally protected privacy of United States
8 citizens or individuals legally in the United
9 States, along with any recommendations by the
10 Director to strengthen such policies and guide-
11 lines.”;

12 (7) in section 709(f)(1) (21 U.S.C.
13 1708(f)(1))—

14 (A) by striking “shall” and inserting
15 “may”;

16 (B) in subparagraph (A), by striking
17 “abuse” and inserting “use or misuse”; and

18 (C) in subparagraph (D)(i), by striking
19 “addiction issues” and inserting “substance use
20 disorders”;

21 (8) in section 709 (21 U.S.C. 1708)—

22 (A) in subsection (f)(2)(B)(iii), by insert-
23 ing after “professionals” the following: “includ-
24 ing experts in evidence-based media campaigns,
25 education, and evaluation”; and

1 (B) in subsection (g), by striking “2023”
2 and inserting “2031”;

3 (9) in section 711 (21 U.S.C. 1710), including
4 the headings, by striking “Command and Control
5 Plan” each place it appears and inserting “Strategic
6 Plan”; and

7 (10) in section 714 (21 U.S.C. 1711), by insert-
8 ing before the period at the end the following: “and
9 \$20,000,000 for each of fiscal years 2025 through
10 2031”.

11 (b) AMENDMENTS TO THE ANTI-DRUG ABUSE ACT
12 OF 1988.—The Anti-Drug Abuse Act of 1988 (Public Law
13 100–690) is amended—

14 (1) in section 1024 (21 U.S.C. 1524)—

15 (A) in subsection (a), by inserting before
16 the period at the end the following: “and
17 \$109,000,000 for each of fiscal years 2025
18 through 2031”; and

19 (B) in subsection (b), by striking “8 per-
20 cent” and inserting “10 percent”; and

21 (2) in section 1032(b) (21 U.S.C. 1532(b))—

22 (A) by striking “\$125,000” each place the
23 term appears and inserting “\$150,000”; and

24 (B) in paragraph (3)—

1 (i) by striking subparagraph (A) and
2 inserting the following:

3 “(A) IN GENERAL.—Subject to subpara-
4 graph (F), the Administrator may award up to
5 2 additional grants under this paragraph to an
6 eligible coalition awarded a grant under para-
7 graph (1) or (2) for any first fiscal year after
8 the end of the 4-year or 9-year period following
9 the period of the initial or subsequent grant
10 under paragraph (1) or (2), as the case may
11 be.”;

12 (ii) in subparagraph (B), by striking
13 “a renewal grant” and inserting “up to 2
14 renewal grants”;

15 (iii) in subparagraph (C), by striking
16 “an additional grant” and inserting “the
17 additional grants”; and

18 (iv) by striking subparagraph (D) and
19 inserting the following:

20 “(D) RENEWAL GRANTS.—Subject to sub-
21 paragraph (F), the Administrator may award a
22 renewal grant to a grant recipient under this
23 paragraph for each fiscal year of the 4-fiscal-
24 year period following the first fiscal year for
25 which an additional grant under this paragraph

1 is awarded in an amount not to exceed the
2 amount of non-Federal funds raised by the coa-
3 lition, including in-kind contributions, for that
4 fiscal year.”.

5 (c) REAUTHORIZATION OF THE NATIONAL COMMU-
6 NITY ANTI-DRUG COALITION INSTITUTE.—Section 4(d)
7 of Public Law 107–82 (21 U.S.C. 1521 note) is amended
8 by striking paragraph (2) and inserting the following:

9 “(2) DISBURSEMENT.—The Director shall,
10 using amounts authorized to be appropriated by sec-
11 tion 1024 of the Anti-Drug Abuse Act of 1988 (21
12 U.S.C. 1524), disburse \$2,500,000 made available
13 under subsection (a), for each of the fiscal years
14 2025 through 2031.”.

15 (d) REAUTHORIZATION OF COMMUNITY-BASED COA-
16 LITION ENHANCEMENT GRANTS TO ADDRESS LOCAL
17 DRUG CRISES.—Section 103 of the Comprehensive Addic-
18 tion and Recovery Act of 2016 (21 U.S.C. 1536) is
19 amended—

20 (1) in subsection (a)—

21 (A) in paragraph (1)—

22 (i) in the heading, by striking “AD-
23 MINISTRATOR” and inserting “ASSISTANT
24 SECRETARY”; and

1 (ii) by striking “Administrator” each
2 place it appears and inserting “Assistant
3 Secretary”;

4 (B) in paragraph (4)(B), by striking
5 “abuse” and inserting “use or misuse”; and

6 (C) in paragraph (5)(A), by striking
7 “abuse” and inserting “use or misuse”;

8 (2) in subsection (b), by striking “Adminis-
9 trator” and inserting “Assistant Secretary”;

10 (3) in subsection (h), by striking “Adminis-
11 trator” and inserting “Assistant Secretary”; and

12 (4) in subsection (i), by inserting before the pe-
13 riod at the end the following: “and \$5,200,000 for
14 each of fiscal years 2025 through 2031”.

15 (e) REPORT REGARDING LIFE-SAVING OPIOID AN-
16 TAGONISTS OR REVERSAL AGENTS.—

17 (1) AMENDMENT.—The Office of National
18 Drug Control Policy Reauthorization Act of 2006
19 (Public Law 109–469) is amended by adding at the
20 end the following new section:

21 **“SEC. 1121. REQUIREMENT FOR LIFE SAVING OPIOID OVER-**
22 **DOSE REVERSAL STUDY.**

23 “(a) FINDING.—Congress finds that it is vital to sup-
24 port access to treatment and emergency intervention tools
25 to address drug addiction while also pursuing strategies

1 to ensure communities have readily available access to life-
2 saving drug overdose reversal medications, including
3 opioid antagonists or reversal agents, such as naloxone,
4 in case of an emergency.

5 “(b) REPORT.—Not later than 180 days after the
6 date of the enactment of this section, the Director of the
7 Office of National Drug Control Policy shall submit to
8 Congress a report that contains the following:

9 “(1) A summary of the relevant roles, respon-
10 sibilities, and authorities of each relevant National
11 Drug Control Program agency to ensure that life-
12 saving drug overdose reversal medications are read-
13 ily available in case of an emergency, including life-
14 saving opioid antagonists or reversal agents, such as
15 naloxone, across the Nation.

16 “(2) A strategy for the Federal Government to
17 ensure that State, local, and Tribal governments,
18 and agencies thereof including law enforcement and
19 public health and safety entities, have life-saving
20 drug overdose reversal medications readily available
21 in case of an emergency, including life-saving opioid
22 antagonists or reversal agents, such as naloxone,
23 which at a minimum identifies—

24 “(A) any Federal and State policies and
25 actions necessary for the relevant National

1 Drug Control Program agencies to take to ad-
2 dress—

3 “(i) the challenges faced by phar-
4 macists, prescription drug providers, dis-
5 pensers (including manufacturers, distribu-
6 tors, and retailers), and other health care
7 providers, to make such medications read-
8 ily available to patients over the counter
9 for emergency use;

10 “(ii) the challenges faced by phar-
11 macists, health care providers, and State
12 health officials to educate the public on the
13 risks and benefits of such medications, in-
14 cluding how to effectively use such medica-
15 tions; and

16 “(iii) the appropriate training of State
17 and local health care providers and first
18 responders on the use of such medications;
19 and

20 “(B) identifies any budgetary resources,
21 personnel resources, licensing requirements, and
22 legal authorities that relevant National Drug
23 Control Program agencies needs to enable the
24 availability of such life-saving emergency drug
25 overdose medications;

1 “(3) A summary of policies in effect before the
2 submission of the report that are administered by—

3 “(A) the Director of the Office National
4 Drug Control Policy;

5 “(B) the Secretary of Health and Human
6 Services; and

7 “(C) each National Drug Control Program
8 agency, as applicable.

9 “(4) A summary of the specific actions taken
10 over the previous 10 years before the submission of
11 the report by the Substance Abuse and Mental
12 Health Services Administration and the Drug En-
13 forcement Administration to coordinate with one an-
14 other and with State health agencies to ensure
15 that—

16 “(A) such treatments, including medica-
17 tions, are accessible to the public; and

18 “(B) appropriate public education on the
19 use of, and the risks and benefits of, such treat-
20 ments, including medications, are readily avail-
21 able.

22 “(c) UPDATES.—Any significant update made to the
23 strategy included in the report required by paragraph
24 (2)(B) after such report is submitted shall be included in

1 the next National Drug Control Strategy submitted to
2 Congress after such update is made.”.

3 (2) TECHNICAL AND CONFORMING AMEND-
4 MENT.—The Table of Contents for the Office of Na-
5 tional Drug Control Policy Reauthorization Act of
6 2006 is amended by adding at the end the following
7 new item:

 “Sec. 1121. Requirement for Life Saving Opioid Overdose Reversal
 Study.”.

8 (f) REPORT ON PILL PRESS MACHINES.—Not later
9 than 120 days after the date of the enactment of this Act,
10 the Director of the Office of Drug Control Policy shall
11 make public a report that includes an analysis of and a
12 description of strategic ways to regulate the shipment of
13 pill press machines and their critical parts using reports
14 previously prepared by the Office.

 Passed the House of Representatives December 5,
2024.

Attest:

Clerk.

118TH CONGRESS
2^D SESSION

H. R. 9598

AN ACT

To amend the Office of National Drug Control Policy Reauthorization Act to reauthorize such Office, and for other purposes.